Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.74 |
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | PDE9A | O76083 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE6C | P51160 | 1/20 | 0.52 |
| ▸ | PDE1A | P54750 | 1/20 | 0.52 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Udenafil SCHEMBL69463 | 0.96 | PDE5A (0.80) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL438563 | 0.96 | PDE5A (0.80) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL3235482 | 0.88 | PDE5A (0.65) | PDE5A | |
| SCHEMBL18269491 | 0.87 | PDE5A (0.62) | PDE5A | |
| Udenafil SCHEMBL30452348 | 0.85 | PDE5A (1.00) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL120993 | 0.85 | PDE5A (1.00) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL18416780 | 0.84 | PDE5A (0.69) | PDE5A | |
| SCHEMBL23641917 | 0.83 | PDE5A (0.72) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8054822 | 0.82 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055636 | 0.82 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581480-B1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS | PFIZER LTD (GB) | 2006-08-23 | — | — | EP | claimed |
| EP-1581480-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASEV INHIBITORS | Pfizer Limited (GB) | 2005-10-05 | — | — | EP | claimed |
| EP-1578735-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | Pfizer Limited (GB) | 2005-09-28 | — | — | EP | claimed |
| US-20040180941-A1 | 3-(1-[3-(1,3-Benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors | PFIZER INC | 2004-09-16 | — | — | US | claimed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | claimed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056750-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA SAS (FR) | 2021-06-03 | — | — | US | disclosed |
| US-20180118784-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-9758549-B2 | Melanocortin receptor ligands modified with hydantoin | IPSEN PHARMA S.A.S. (FR) | 2017-09-12 | — | — | US | disclosed |
| EP-2148692-B1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA SAS (FR) | 2017-01-25 | — | — | EP | disclosed |
| US-20160176925-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2016-06-23 | — | — | US | disclosed |
| US-9296783-B2 | Melanocortin receptor ligands modified with hydantoin | IPSEN PHARMA S.A.S. (FR) | 2016-03-29 | — | — | US | disclosed |
| US-20040180941-A1 | 3-(1-[3-(1,3-Benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-20040157847-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-08-12 | — | — | US | disclosed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056750-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004054560-A1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | PDE5A 13/4885PDE2A 1/4885PDE9A 17/4885 |
| US-20040180941-A1 | 3-(1-[3-(1,3-Benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors | MME, PREP, DNPEP | PDE5A 451/4885PDE2A 732/4885PDE9A 955/4885 |
| US-20180118784-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | PDE5A 1089/4885PDE2A 1539/4885PDE9A 1769/4885 |
| US-20210163536-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | PDE5A 1089/4885PDE2A 1539/4885PDE9A 1769/4885 |
| US-20160176925-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | PDE5A 1089/4885PDE2A 1539/4885PDE9A 1769/4885 |
| US-20040157847-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | PDE5A 13/4885PDE2A 1/4885PDE9A 17/4885 |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | PDE5A 184/4885PDE2A 210/4885PDE9A 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.